199 related articles for article (PubMed ID: 22227882)
1. A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro.
Hughes A; Kleine-Albers J; Helfrich MH; Ralston SH; Rogers MJ
Calcif Tissue Int; 2012 Feb; 90(2):151-62. PubMed ID: 22227882
[TBL] [Abstract][Full Text] [Related]
2. Adenosine A
Mediero A; Wilder T; Shah L; Cronstein BN
FASEB J; 2018 Jul; 32(7):3487-3501. PubMed ID: 29394106
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin 3d and semaphorin 3e direct endothelial motility through distinct molecular signaling pathways.
Aghajanian H; Choi C; Ho VC; Gupta M; Singh MK; Epstein JA
J Biol Chem; 2014 Jun; 289(26):17971-9. PubMed ID: 24825896
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin-3E attenuates neointimal formation via suppressing VSMCs migration and proliferation.
Wu JH; Li Y; Zhou YF; Haslam J; Elvis ON; Mao L; Xia YP; Hu B
Cardiovasc Res; 2017 Dec; 113(14):1763-1775. PubMed ID: 29016743
[TBL] [Abstract][Full Text] [Related]
5. Class 3 semaphorins are transcriptionally regulated by 1,25(OH)
Ryynänen J; Kriebitzsch C; Meyer MB; Janssens I; Pike JW; Verlinden L; Verstuyf A
J Steroid Biochem Mol Biol; 2017 Oct; 173():185-193. PubMed ID: 28189595
[TBL] [Abstract][Full Text] [Related]
6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
7. Neuroimmune guidance cue Semaphorin 3E is expressed in atherosclerotic plaques and regulates macrophage retention.
Wanschel A; Seibert T; Hewing B; Ramkhelawon B; Ray TD; van Gils JM; Rayner KJ; Feig JE; O'Brien ER; Fisher EA; Moore KJ
Arterioscler Thromb Vasc Biol; 2013 May; 33(5):886-93. PubMed ID: 23430613
[TBL] [Abstract][Full Text] [Related]
8. Nrp2 deficiency leads to trabecular bone loss and is accompanied by enhanced osteoclast and reduced osteoblast numbers.
Verlinden L; Kriebitzsch C; Beullens I; Tan BK; Carmeliet G; Verstuyf A
Bone; 2013 Aug; 55(2):465-75. PubMed ID: 23598046
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
10. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of semaphorin as a novel strategy for therapeutic angiogenesis.
Moriya J; Minamino T; Tateno K; Okada S; Uemura A; Shimizu I; Yokoyama M; Nojima A; Okada M; Koga H; Komuro I
Circ Res; 2010 Feb; 106(2):391-8. PubMed ID: 19940264
[TBL] [Abstract][Full Text] [Related]
12. Neuronal chemorepellent Semaphorin 3E inhibits human airway smooth muscle cell proliferation and migration.
Movassagh H; Shan L; Halayko AJ; Roth M; Tamm M; Chakir J; Gounni AS
J Allergy Clin Immunol; 2014 Feb; 133(2):560-7. PubMed ID: 23932461
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2.
Granholm S; Henning P; Lindholm C; Lerner UH
Bone; 2013 Jan; 52(1):83-92. PubMed ID: 23017661
[TBL] [Abstract][Full Text] [Related]
14. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
15. Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling.
Koskinen C; Persson E; Baldock P; Stenberg Å; Boström I; Matozaki T; Oldenborg PA; Lundberg P
J Biol Chem; 2013 Oct; 288(41):29333-44. PubMed ID: 23990469
[TBL] [Abstract][Full Text] [Related]
16. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
[TBL] [Abstract][Full Text] [Related]
17. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells.
Schulze J; Bickert T; Beil FT; Zaiss MM; Albers J; Wintges K; Streichert T; Klaetschke K; Keller J; Hissnauer TN; Spiro AS; Gessner A; Schett G; Amling M; McKenzie AN; Horst AK; Schinke T
J Bone Miner Res; 2011 Apr; 26(4):704-17. PubMed ID: 20939024
[TBL] [Abstract][Full Text] [Related]
19. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro.
Balani D; Aeberli D; Hofstetter W; Seitz M
Arthritis Rheum; 2013 Feb; 65(2):436-46. PubMed ID: 23124514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
